
EquitySector - HealthcareVery High Risk
Regular
NAV (20-Mar-26)
Returns (Since Inception)
Fund Size
₹4,077 Cr
Expense Ratio
1.93%
ISIN
INF200K01446
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
31 Dec 2004
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+1.61%
+3.55% (Cat Avg.)
3 Years
+24.85%
+24.47% (Cat Avg.)
5 Years
+17.49%
+15.72% (Cat Avg.)
10 Years
+12.03%
+13.45% (Cat Avg.)
Since Inception
+14.86%
— (Cat Avg.)
| Equity | ₹3,954.16 Cr | 96.99% |
| Debt | ₹2.89 Cr | 0.07% |
| Others | ₹119.62 Cr | 2.93% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹434.25 Cr | 10.65% |
| Divi's Laboratories Ltd | Equity | ₹307.61 Cr | 7.55% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹234.65 Cr | 5.76% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹196.55 Cr | 4.82% |
| Acutaas Chemicals Ltd | Equity | ₹194.29 Cr | 4.77% |
| Torrent Pharmaceuticals Ltd | Equity | ₹173.33 Cr | 4.25% |
| Lupin Ltd | Equity | ₹172.64 Cr | 4.23% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹157.1 Cr | 3.85% |
| Biocon Ltd | Equity | ₹146.18 Cr | 3.59% |
| Laurus Labs Ltd | Equity | ₹142.01 Cr | 3.48% |
| Aether Industries Ltd | Equity | ₹134.2 Cr | 3.29% |
| Fortis Healthcare Ltd | Equity | ₹131.97 Cr | 3.24% |
| Treps | Cash - Repurchase Agreement | ₹129.96 Cr | 3.19% |
| Lonza Group Ltd ADR | Equity | ₹126.12 Cr | 3.09% |
| Mankind Pharma Ltd | Equity | ₹121.37 Cr | 2.98% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹119.21 Cr | 2.92% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹113.56 Cr | 2.79% |
| Alkem Laboratories Ltd | Equity | ₹112.79 Cr | 2.77% |
| Anthem Biosciences Ltd | Equity | ₹109.38 Cr | 2.68% |
| Gland Pharma Ltd | Equity | ₹109.33 Cr | 2.68% |
| Concord Biotech Ltd | Equity | ₹87.88 Cr | 2.16% |
| Sudeep Pharma Ltd | Equity | ₹86.9 Cr | 2.13% |
| Poly Medicure Ltd | Equity | ₹80.39 Cr | 1.97% |
| Sai Life Sciences Ltd | Equity | ₹79.86 Cr | 1.96% |
| Abbott India Ltd | Equity | ₹79.59 Cr | 1.95% |
| Ajanta Pharma Ltd | Equity | ₹74.85 Cr | 1.84% |
| Nephrocare Health Services Ltd | Equity | ₹47.5 Cr | 1.17% |
| Cohance Lifesciences Ltd | Equity | ₹37.19 Cr | 0.91% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹33.67 Cr | 0.83% |
| Gufic Biosciences Ltd | Equity | ₹28.19 Cr | 0.69% |
| Medplus Health Services Ltd | Equity | ₹25.43 Cr | 0.62% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹25.11 Cr | 0.62% |
| Corona Remedies Ltd | Equity | ₹15.87 Cr | 0.39% |
| Pfizer Ltd | Equity | ₹15.19 Cr | 0.37% |
| Net Receivable / Payable | Cash - Collateral | ₹-10.33 Cr | 0.25% |
| 19/11/2026 Maturing 364 DTB | Bond - Gov't/Treasury | ₹2.89 Cr | 0.07% |
Large Cap Stocks
33.03%
Mid Cap Stocks
24.92%
Small Cap Stocks
35.95%
AAA
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹3,625.67 Cr | 88.94% |
| Basic Materials | ₹328.5 Cr | 8.06% |
Standard Deviation
This fund
14.34%
Cat. avg.
16.02%
Lower the better
Sharpe Ratio
This fund
1.27
Cat. avg.
1.11
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
2.01
Higher the better
Since June 2011
ISIN INF200K01446 | Expense Ratio 1.93% | Exit Load No Charges | Fund Size ₹4,077 Cr | Age 21 years 2 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹12,90,067 Cr
Address
C-38 & 39, G Block, Bandra Kurla Complex, Mumbai, 400 051
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments